Description
Application
Cationic Lipid Pairs Enhance Liver-to-Lung Tropism of Lipid Nanoparticles for In Vivo mRNA Delivery.: ALC-0315 plays a critical role in this study, enhancing the delivery efficiency of mRNA therapies from liver to lung. This research could lead to improved treatment options for various pulmonary diseases (Zeng et al., 2024).
Engineering LNPs with polysarcosine lipids for mRNA delivery.: Demonstrates ALC-0315′s application in designing lipid nanoparticles that efficiently deliver mRNA, showcasing potential advancements in gene therapy (Kang et al., 2024).
Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy.: Utilizes ALC-0315 in the development of lipid nanoparticles that activate under tumor-specific conditions to deliver immunotherapeutic agents, offering a targeted approach to cancer treatment (Jiang et al., 2024).
Packaging
5 mL Amber Glass Screw Cap Vial (890900O-25MG)
5 mL Amber Glass Screw Cap Vial (890900O-50MG)
5 mL Amber Glass Screw Cap Vial (890900O-100MG)
5 mL Amber Glass Screw Cap Vial (890900O-200MG)
5 mL Amber Glass Screw Cap Vial (890900O-500MG)
30 mL Amber Glass Screw Cap Vial(890900O-1G)
Other Notes
Quantities limited to 50G in a calendar year per customer.
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC